Nasdaq
$1.40▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $68.9MShares out 49.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.29After-hours26.09.30 06:004Ownership#●●●#●●●
MEDICINOVA INC
3D Opportunity Master Fund and 3D Investment Partners Pte. Ltd., major shareholders of MediciNova, reported changes in their beneficial ownership as of September 25, 2026. This filing is a Form 4 statement regarding the changes in holdings by insiders and major shareholders.…more
$1.40+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29After-hours26.09.30 06:00SCHEDULE 13D/AOwnership
MEDICINOVA INC
3D Investment Partners Pte. Ltd. and 3D Opportunity Master Fund have filed a Schedule 13D regarding their ownership of MediciNova, Inc. common stock. This filing serves to formalize the joint filing agreement between the reporting persons.…more
$1.40+0.00%vs prev closeView filingShare - 9.28After-hours26.09.29 05:058-KKey event
MEDICINOVA INC
MediciNova, Inc. has amended its office lease agreement, extending the term from January 31, 2027, to April 30, 2030. Under the terms of the amendment, the company has agreed to rent increases effective February 1, 2027.…more
$1.40+0.00%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 19:00#●●●#●●●
MediciNova Provides Update on MN-001 Phase 2 Results and Pipeline Progress…more
MediciNova reported that its Phase 2 trial for MN-001 in NAFLD did not meet primary endpoints despite observing some improvements in lipid markers. The company remains focused on its lead asset MN-166, with topline results for its ALS trial expected by year-end.…more
$1.40+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 19:00
●●●●●●●● ●●●●● ●●●●●●
MediciNova announced that its management will participate in the Maxim Growth Summit to hold one-on-one meetings with investors. This is a routine corporate event participation and does not provide immediate material impact on the stock.…more
$1.40+0.00%vs prev close - 9.28Regular26.09.29 00:10
●●●●●●●● ●●●●● ●●●●●●
MediciNova reported mixed Phase 2 results for its MN-001 drug, showing improvements in lipid markers but failing to achieve statistical significance in liver fat reduction. The stock fell sharply as the clinical data failed to meet investor expectations.…more
$1.40+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report